Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review)

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar : PubMed/NCBI

World Health Organization: Global cancer burden growing, amidst mounting need for services. 2024.

Siegel RL, Kratzer TB, Giaquinto AN, Sung H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45. 2025. View Article : Google Scholar : PubMed/NCBI

de Visser KE and Joyce JA: The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI

Cai Z, Yin Y, Shen C, Wang J, Yin X, Chen Z, Zhou Y and Zhang B: Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years. Surg Oncol. 27:563–574. 2018. View Article : Google Scholar : PubMed/NCBI

Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK and Weinberg RA: The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 10:eaan34642018. View Article : Google Scholar : PubMed/NCBI

Yu WD, Sun G, Li J, Xu J and Wang X: Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 452:66–70. 2019. View Article : Google Scholar

Pich O, Muiños F, Lolkema MP, Steeghs N, Gonzalez-Perez A and Lopez-Bigas N: The mutational footprints of cancer therapies. Nat Genet. 51:1732–1740. 2019. View Article : Google Scholar : PubMed/NCBI

Sonis ST: Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 45:1015–1020. 2009. View Article : Google Scholar : PubMed/NCBI

Xiao H, Xiong L, Song X, Jin P, Chen L, Chen X, Yao H, Wang Y and Wang L: Angelica sinensis polysaccharides ameliorate stress-induced premature senescence of hematopoietic cell via protecting bone marrow stromal cells from oxidative injuries caused by 5-fluorouracil. Int J Mol Sci. 18:22652017. View Article : Google Scholar : PubMed/NCBI

Wang Y, Probin V and Zhou DH: Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2:271–279. 2006. View Article : Google Scholar : PubMed/NCBI

Ryan JL: Ionizing radiation: The good, the bad, and the ugly. J Invest Dermatol. 132:985–993. 2012. View Article : Google Scholar : PubMed/NCBI

Dracham CB, Shankar A and Madan R: Radiation induced secondary malignancies: A review article. Radiat Oncol J. 36:85–94. 2018. View Article : Google Scholar : PubMed/NCBI

Gupta K, Walton R and Kataria SP: Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 26:1002782021. View Article : Google Scholar

Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA and Klinger FG: Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 25:673–693. 2019. View Article : Google Scholar : PubMed/NCBI

Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F and Capellá G: Recent advances in cancer therapy: An overview. Curr Pharm Des. 16:3–10. 2010. View Article : Google Scholar

Cavalcanti IDL and Soares JCS: Advances in cancer treatment: From systemic chemotherapy to targeted therapy. Springer Nature. 1–109. 2021.

Baudino TA: Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol. 12:3–20. 2015. View Article : Google Scholar

Lollini PL, Cavallo F, Nanni P and Forni G: Vaccines for tumour prevention. Nat Rev Cancer. 6:204–216. 2006. View Article : Google Scholar : PubMed/NCBI

Pinho MP, Sundarasetty BS, Bergami-Santos PC, Steponavicius-Cruz K, Ferreira AK, Stripecke R and Barbuto JAM: Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Cytotherapy. 18:570–580. 2016. View Article : Google Scholar

Guzhova IV and Margulis BA: HSP70-based anti-cancer immunotherapy. Hum Vaccin Immunother. 12:2529–2535. 2016. View Article : Google Scholar : PubMed/NCBI

Howell LM and Forbes NS: Bacteria-based immune therapies for cancer treatment. Semin Cancer Biol. 86:1163–1178. 2022. View Article : Google Scholar

Eshhar Z: The T-body approach: Redirecting T cells with antibody specificity. Handb Exp Pharmacol. 181:329–342. 2008. View Article : Google Scholar

Dai R, Liu M, Nik Nabil WN, Xi Z and Xu H: Mycomedicine: A unique class of natural products with potent anti-tumour bioactivities. Molecules. 26:11132021. View Article : Google Scholar : PubMed/NCBI

Lau TTY, Sefid Dashti ZJ, Titmuss E, Pender A, Topham JT, Bridgers J, Loree JM, Feng X, Pleasance ED, Renouf DJ, et al: The neoantigen landscape of the coding and noncoding cancer genome space. J Mol Diagn. 24:609–618. 2022. View Article : Google Scholar : PubMed/NCBI

Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, et al: Challenges in neoantigen-directed therapeutics. Cancer Cell. 41:15–40. 2023. View Article : Google Scholar

Sia D, Villanueva A, Friedman SL and Llovet JM: Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 152:745–761. 2017. View Article : Google Scholar

Sánchez-Danés A and Blanpain C: Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer. 18:549–561. 2018. View Article : Google Scholar

Kim J, Lee BJ, Moon S, Lee H, Lee J, Kim BS, Jung K, Seo H and Chung Y: Strategies to overcome hurdles in cancer immunotherapy. Biomater Res. 28:00802024. View Article : Google Scholar

Farhadi Rad H, Tahmasebi H, Javani S, Hemati M, Zakerhamidi D, Hosseini M, Alibabaei F, Banihashemian SZ, Oksenych V and Eslami M: Microbiota and cytokine modulation: Innovations in enhancing anticancer immunity and personalized cancer therapies. Biomedicines. 12:27762024. View Article : Google Scholar

Ritu, Chandra P and Das A: Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clin Exp Med. 23:4297–4322. 2023. View Article : Google Scholar : PubMed/NCBI

Luo Q, Zhang L, Luo C and Jiang M: Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 454:191–203. 2019. View Article : Google Scholar : PubMed/NCBI

Weiner GJ: Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 15:361–370. 2015. View Article : Google Scholar :

Wei G, Zhang H, Zhao H, Wang J, Wu N, Li L, Wu J and Zhang D: Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy. Cancer Lett. 511:68–76. 2021. View Article : Google Scholar : PubMed/NCBI

Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 20:211–220. 2008. View Article : Google Scholar : PubMed/NCBI

Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al: Exploiting the mutanome for tumor vaccination. Cancer Res. 72:1081–1091. 2012. View Article : Google Scholar

Rosenberg SA and Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348:62–68. 2015. View Article : Google Scholar : PubMed/NCBI

Zhang J and Wang L: The emerging world of TCR-T cell trials against cancer: A systematic review. Technol Cancer Res Treat. 18:15330338198310682019. View Article : Google Scholar : PubMed/NCBI

Zhao QJ, Jiang Y, Xiang SX, Kaboli PJ, Shen J, Zhao YS, Wu X, Du FK, Li MX, Cho CH, et al: Engineered TCR-T cell immunotherapy in anticancer precision medicine: Pros and cons. Front Immunol. 12:6587532021. View Article : Google Scholar : PubMed/NCBI

Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI

Daher M, Melo Garcia L, Li Y and Rezvani K: CAR-NK cells: The next wave of cellular therapy for cancer. Clin Transl Immunology. 10:e12742021. View Article : Google Scholar : PubMed/NCBI

Chen XT, Yang J, Wang LF and Liu BR: Personalized neoantigen vaccination with synthetic long peptides: Recent advances and future perspectives. Theranostics. 10:6011–6023. 2020. View Article : Google Scholar : PubMed/NCBI

Li L, Goedegebuure SP and Gillanders WE: Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 28(Suppl 12): xii11–xii17. 2017. View Article : Google Scholar

Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C and Ott PA: Neoantigen-directed therapeutics in the clinic: Where are we? Trends Cancer. 9:503–519. 2023. View Article : Google Scholar

Luo Y, Zhou H, Mizutani M, Mizutani N, Liu C, Xiang R and Reisfeld RA: A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res. 65:3419–3427. 2005. View Article : Google Scholar : PubMed/NCBI

Ribatti D: The concept of immune surveillance against tumors: The first theories. Oncotarget. 8:7175–7180. 2017. View Article : Google Scholar

Gross L: Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:326–333. 1943.

Baldwin RW: Tumour-specific immunity against spontaneous rat tumours. Int J Cancer. 1:257–264. 1966. View Article : Google Scholar

Dietrich CH, Allen JM, Lemmon AR, Lemmon EM, Takiya DM, Evangelista O, Walden KKO, Grady PGS and Johnson KP: Anchored hybrid enrichment-based phylogenomics of leafhoppers and treehoppers (Hemiptera: Cicadomorpha: Membracoidea). Insect Syst Divers. 1:57–72. 2017. View Article : Google Scholar

Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL and Griffith M: Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11:562019. View Article : Google Scholar

Aljabali AAA, Hamzat Y, Alqudah A and Alzoubi L: Neoantigen vaccines: Advancing personalized cancer immunotherapy. Explor Immunol. 5:10031902025. View Article : Google Scholar

Fennemann FL, de Vries IJM, Figdor CG and Verdoes M: Attacking tumors from all sides: Personalized multiplex vaccines to tackle intratumor heterogeneity. Front Immunol. 10:8242019. View Article : Google Scholar

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al: Neoantigen vaccine: An emerging tumor immunotherapy. Mol Cancer. 18:1282019. View Article : Google Scholar : PubMed/NCBI

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 618:144–150. 2023. View Article : Google Scholar

Ehx G and Perreault C: Discovery and characterization of actionable tumor antigens. Genome Med. 11:292019. View Article : Google Scholar

Finn OJ: Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res. 5:347–354. 2017. View Article : Google Scholar : PubMed/NCBI

Sotirov S and Dimitrov I: Tumor-derived antigenic peptides as potential cancer vaccines. Int J Mol Sci. 25:49342024. View Article : Google Scholar

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI

Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, et al: Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 27:515–525. 2021. View Article : Google Scholar :

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 565:234–239. 2019. View Article : Google Scholar :

Ali OA, Lewin SA, Dranoff G and Mooney DJ: Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 4:95–100. 2016. View Article : Google Scholar

Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD and Knutson KL: Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 74:2974–2985. 2014. View Article : Google Scholar

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar

Qiu Z, Chen Z, Zhang C and Zhong W: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 8:192019. View Article : Google Scholar :

Zou W, Wolchok JD and Chen L: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 8:328rv42016. View Article : Google Scholar : PubMed/NCBI

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, et al: Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 125:4172–4180. 2019. View Article : Google Scholar

Lin G, Elkashif A, Saha C, Coulter JA, Dunne NJ and McCarthy HO: Key considerations for a prostate cancer mRNA vaccine. Crit Rev Oncol Hematol. 208:1046432025. View Article : Google Scholar : PubMed/NCBI

Blum JS, Wearsch PA and Cresswell P: Pathways of antigen processing. Annu Rev Immunol. 31:443–473. 2013. View Article : Google Scholar : PubMed/NCBI

Babbitt BP, Allen PM, Matsueda G, Haber E and Unanue ER: Binding of immunogenic peptides to Ia histocompatibility molecules. Nature. 317:359–361. 1985. View Article : Google Scholar

Abdel-Aal ABM, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ and Boons GJ: Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem. 15:1508–1513. 2014. View Article : Google Scholar

Vlad AM, Kettel JC, Alajez NM, Carlos CA and Finn OJ: MUC1 immunobiology: From discovery to clinical applications. Adv Immunol. 82:249–293. 2004. View Article : Google Scholar

Arab A, Yazdian-Robati R and Behravan J: HER2-positive breast cancer immunotherapy: A focus on vaccine development. Arch Immunol Ther Exp (Warsz). 68:22020. View Article : Google Scholar

Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT and Papamichail M: Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother. 55:85–95. 2006. View Article : Google Scholar

Zanetti M: A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol. 14:115–128. 2017. View Article : Google Scholar

Slingluff CL Jr, Chianese-Bullock KA, Bullock TNJ, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M and Engelhard VH: Immunity to melanoma antigens: From self-tolerance to immunotherapy. Adv Immunol. 90:243–295. 2006. View Article : Google Scholar

Guo Q, Wang J, Xiao J, Wang L, Hu X, Yu W, Song G, Lou J and Chen JF: Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. Mol Cancer. 17:1312018. View Article : Google Scholar :

Hollingsworth RE and Jansen K: Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 4:72019. View Article : Google Scholar

Malacopol AT and Holst PJ: Cancer vaccines: Recent insights and future directions. Int J Mol Sci. 25:112562024. View Article : Google Scholar : PubMed/NCBI

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, et al: Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clin Cancer Res. 22:2734–2743. 2016. View Article : Google Scholar

Chen P, Fang QX, Chen DB and Chen HS: Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol. 13:673–683. 2021. View Article : Google Scholar

Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L and Hung SI: Recent development and clinical application of cancer vaccine: Targeting neoantigens. J Immunol Res. 2018:43258742018. View Article : Google Scholar

Vormehr M, Türeci Ö and Sahin U: Harnessing tumor mutations for truly individualized cancer vaccines. Annu Rev Med. 70:395–407. 2019. View Article : Google Scholar : PubMed/NCBI

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, et al: Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis. Lancet Oncol. 18:1009–1021. 2017. View Article : Google Scholar : PubMed/NCBI

Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, et al: Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 25:767–775. 2019. View Article : Google Scholar :

Zhang J, White NM, Schmidt HK, Fulton RS, Tomlinson C, Warren WC, Wilson RK and Maher CA: INTEGRATE: Gene fusion discovery using whole genome and transcriptome data. Genome Res. 26:108–118. 2016. View Article : Google Scholar :

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar

Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. 2017. View Article : Google Scholar

Borden ES, Buetow KH, Wilson MA and Hastings KT: Cancer neoantigens: Challenges and future directions for prediction, prioritization, and validation. Front Oncol. 12:8368212022. View Article : Google Scholar

Anczuków O and Krainer AR: Splicing-factor alterations in cancers. RNA. 22:1285–1301. 2016. View Article : Google Scholar : PubMed/NCBI

Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O and Sander C; Cancer Genome Atlas Research Network, Gunnar Rätsch: Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 34:211–224 e6. 2018. View Article : Google Scholar

Cheng R, Xu Z, Luo M, Wang P, Cao H, Jin X, Zhou W, Xiao L and Jiang Q: Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development. Brief Bioinform. 23:bbab5532022. View Article : Google Scholar

Weller C, Bartok O, McGinnis CS, Palashati H, Chang TG, Malko D, Shmueli MD, Nagao A, Hayoun D, Murayama A, et al: Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell. S1535-6108(25)00082-02025.Epub ahead of print.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER and Linette GP: Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 348:803–808. 2015. View Article : Google Scholar :

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547:222–226. 2017. View Article : Google Scholar : PubMed/NCBI

Hacohen N, Fritsch EF, Carter TA, Lander ES and Wu CJ: Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 1:11152013. View Article : Google Scholar

Capietto AH, Hoshyar R and Delamarre L: Sources of cancer neoantigens beyond single-nucleotide variants. Int J Mol Sci. 23:101312022. View Article : Google Scholar : PubMed/NCBI

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, et al: A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 512:324–327. 2014. View Article : Google Scholar : PubMed/NCBI

Wang QJ, Yu Z, Griffith K, Hanada KI, Restifo NP and Yang JC: Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 4:204–214. 2016. View Article : Google Scholar

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, et al: Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 215:141–157. 2018. View Article : Google Scholar :

Wang Y, Shi T, Song X, Liu B and Wei J: Gene fusion neoantigens: Emerging targets for cancer immunotherapy. Cancer Lett. 506:45–54. 2021. View Article : Google Scholar

Wei Z, Zhou C, Zhang Z, Guan M, Zhang C, Liu Z and Liu Q: The landscape of tumor fusion neoantigens: A pan-cancer analysis. iScience. 21:249–260. 2019. View Article : Google Scholar : PubMed/NCBI

Dai X, Theobard R, Cheng H, Xing M and Zhang J: Fusion genes: A promising tool combating against cancer. Biochim Biophys Acta Rev Cancer. 1869:149–160. 2018. View Article : Google Scholar : PubMed/NCBI

Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG and Serody JS: Alternative tumour-specific antigens. Nat Rev Cancer. 19:465–478. 2019. View Article : Google Scholar :

Diederichs S, Bartsch L, Berkmann JC, Fröse K, Heitmann J, Hoppe C, Iggena D, Jazmati D, Karschnia P, Linsenmeier M, et al: The dark matter of the cancer genome: Aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol Med. 8:442–457. 2016. View Article : Google Scholar :

Laumont CM, Vincent K, Hesnard L, Audemard É, Bonneil É, Laverdure JP, Gendron P, Courcelles M, Hardy MP, Côté C, et al: Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 10:eaau55162018. View Article : Google Scholar

Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, Zeng X, Wang J, Yang B, Zhang Y, et al: Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 625:593–602. 2024. View Article : Google Scholar

Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 19:747–752. 2013. View Article : Google Scholar

van Buuren MM, Calis JJ and Schumacher TN: High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology. 3:e288362014. View Article : Google Scholar : PubMed/NCBI

Biswas N, Chakrabarti S, Padul V, Jones LD and Ashili S: Designing neoantigen cancer vaccines, trials, and outcomes. Front Immunol. 14:11054202023. View Article : Google Scholar :

Roudko V, Greenbaum B and Bhardwaj N: Computational prediction and validation of tumor-associated neoantigens. Front Immunol. 11:272020. View Article : Google Scholar : PubMed/NCBI

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 515:572–576. 2014. View Article : Google Scholar : PubMed/NCBI

Chen S, Zhou Y, Chen Y and Gu J: fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 34:i884–i890. 2018. View Article : Google Scholar :

Chen S: Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp. Imeta. 2:e1072023. View Article : Google Scholar : PubMed/NCBI

Li H and Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI

Langmead B and Salzberg SL: Fast gapped-read alignment with Bowtie 2. Nat Methods. 9:357–359. 2012. View Article : Google Scholar : PubMed/NCBI

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21. 2013. View Article : Google Scholar

Kim D, Langmead B and Salzberg SL: HISAT: A fast spliced aligner with low memory requirements. Nat Methods. 12:357–360. 2015. View Article : Google Scholar :

Pertea M, Kim D, Pertea GM, Leek JT and Salzberg SL: Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 11:1650–1667. 2016. View Article : Google Scholar : PubMed/NCBI

Kim D, Paggi JM, Park C, Bennett C and Salzberg SL: Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 37:907–915. 2019. View Article : Google Scholar : PubMed/NCBI

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL: TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14:R362013. View Article : Google Scholar : PubMed/NCBI

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome Project Data Processing Subgroup: The sequence alignment/map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI

Shumate A, Wong B, Pertea G and Pertea M: Improved transcriptome assembly using a hybrid of long and short reads with StringTie. PLoS Comput Biol. 18:e10097302022. View Article : Google Scholar : PubMed/NCBI

van der Auwera G and O'Connor BD: Genomics in the cloud: Using docker, GATK, and WDL in Terra. O'Reilly Media, Incorporated; 2020

Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK: VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22:568–576. 2012. View Article : Google Scholar

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC and Dry JR: VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44:e1082016. View Article : Google Scholar : PubMed/NCBI

Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, Chen X, Kim Y, Beyter D, Krusche P and Saunders CT: Strelka2: Fast and accurate calling of germline and somatic variants. Nat Methods. 15:591–594. 2018. View Article : Google Scholar : PubMed/NCBI

Haas BJ, Dobin A, Stransky N, Li B, Yang X, Tickle T, Bankapur A, Ganote C, Doak TG, Pochet N, et al: STAR-fusion: Fast and accurate fusion transcript detection from RNA-Seq. bioRxiv: 120295. 2017.

Yang H and Wang K: Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 10:1556–1566. 2015. View Article : Google Scholar : PubMed/NCBI

Mayakonda A, Lin DC, Assenov Y, Plass C and Koeffler HP: Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28:1747–1756. 2018. View Article : Google Scholar : PubMed/NCBI

Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI

Gubin MM, Artyomov MN, Mardis ER and Schreiber RD: Tumor neoantigens: Building a framework for personalized cancer immunotherapy. J Clin Invest. 125:3413–3421. 2015. View Article : Google Scholar : PubMed/NCBI

Shiina T, Hosomichi K, Inoko H and Kulski JK: The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 54:15–39. 2009. View Article : Google Scholar : PubMed/NCBI

Klein J and Sato A: The HLA system. First of two parts. N Engl J Med. 343:702–709. 2000. View Article : Google Scholar : PubMed/NCBI

Neefjes J, Jongsma M, Paul P and Bakke O: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 11:823–836. 2011. View Article : Google Scholar : PubMed/NCBI

Aurisicchio L, Pallocca M, Ciliberto G and Palombo F: The perfect personalized cancer therapy: Cancer vaccines against neoantigens. J Exp Clin Cancer Res. 37:862018. View Article : Google Scholar : PubMed/NCBI

Bontadini A: HLA techniques: Typing and antibody detection in the laboratory of immunogenetics. Methods. 56:471–476. 2012. View Article : Google Scholar : PubMed/NCBI

De Mattos-Arruda L, Vazquez M, Finotello F, Lepore R, Porta E, Hundal J, Amengual-Rigo P, Ng CKY, Valencia A, Carrillo J, et al: Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO precision medicine working group. Ann Oncol. 31:978–990. 2020. View Article : Google Scholar : PubMed/NCBI

Hosomichi K, Shiina T, Tajima A and Inoue I: The impact of next-generation sequencing technologies on HLA research. J Hum Genet. 60:665–673. 2015. View Article : Google Scholar : PubMed/NCBI

Danzer M, Niklas N, Stabentheiner S, Hofer K, Pröll J, Stückler C, Raml E, Polin H and Gabriel C: Rapid, scalable and highly automated HLA genotyping using next-generation sequencing: A transition from research to diagnostics. BMC Genomics. 14:2212013. View Article : Google Scholar : PubMed/NCBI

Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, Mostafa AA, Pando MJ, Usenko CY, Bettinotti MP, et al: Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs. HLA. 94:296–306. 2019. View Article : Google Scholar : PubMed/NCBI

Wittig M, Anmarkrud JA, Kässens JC, Koch S, Forster M, Ellinghaus E, Hov JR, Sauer S, Schimmler M, Ziemann M, et al: Development of a high-resolution NGS-based HLA-typing and analysis pipeline. Nucleic Acids Res. 43:e702015. View Article : Google Scholar :

Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, Türeci O, Diken M, Castle JC and Sahin U: HLA typing from RNA-seq sequence reads. Genome Med. 4:1022012. View Article : Google Scholar : PubMed/NCBI

Warren RL, Choe G, Freeman DJ, Castellarin M, Munro S, Moore R and Holt RA: Derivation of HLA types from shotgun sequence datasets. Genome Med. 4:952012. View Article : Google Scholar : PubMed/NCBI

Warren RL: HLA predictions from long sequence read alignments, streamed directly into HLAminer. arXiv: 2209.09155. 2022.

Kim HJ and Pourmand N: HLA typing from RNA-seq data using hierarchical read weighting [corrected]. PLoS One. 8:e678852013. View Article : Google Scholar

Liu C, Yang X, Duffy B, Mohanakumar T, Mitra RD, Zody MC and Pfeifer JD: ATHLATES: Accurate typing of human leukocyte antigen through exome sequencing. Nucleic Acids Res. 41:e1422013. View Article : Google Scholar :

Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M and Kohlbacher O: OptiType: Precision HLA typing from next-generation sequencing data. Bioinformatics. 30:3310–3316. 2014. View Article : Google Scholar

Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S, et al: Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 33:1152–1158. 2015. View Article : Google Scholar : PubMed/NCBI

Huang Y, Yang J, Ying D, Zhang Y, Shotelersuk V, Hirankarn N, Sham PC, Lau YL and Yang W: HLAreporter: A tool for HLA typing from next generation sequencing data. Genome Med. 7:252015. View Article : Google Scholar :

Nariai N, Kojima K, Saito S, Mimori T, Sato Y, Kawai Y, Yamaguchi-Kabata Y, Yasuda J and Nagasaki M: HLA-VBSeq: Accurate HLA typing at full resolution from whole-genome sequencing data. BMC Genomics. 16(Suppl 2): S72015. View Article : Google Scholar : PubMed/NCBI

Xie C, Yeo ZX, Wong M, Piper J, Long T, Kirkness EF, Biggs WH, Bloom K, Spellman S, Vierra-Green C, et al: Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc Natl Acad Sci USA. 114:8059–8064. 2017. View Article : Google Scholar : PubMed/NCBI

Kawaguchi S, Higasa K, Shimizu M, Yamada R and Matsuda F: HLA-HD: An accurate HLA typing algorithm for nextgeneration sequencing data. Hum Mutat. 38:788–797. 2017. View Article : Google Scholar : PubMed/NCBI

Kawaguchi S, Higasa K, Yamada R and Matsuda F: Comprehensive HLA typing from a current allele database using next-generation sequencing data. Methods Mol Biol. 1802:225–233. 2018. View Article : Google Scholar

Kawaguchi S and Matsuda F: High-definition genomic analysis of HLA genes via comprehensive HLA allele genotyping. Methods Mol Biol. 2131:31–38. 2020. View Article : Google Scholar : PubMed/NCBI

Ka S, Lee S, Hong J, Cho Y, Sung J, Kim HN, Kim HL and Jung J: HLAscan: Genotyping of the HLA region using next-generation sequencing data. BMC Bioinformatics. 18:2582017. View Article : Google Scholar :

Hayashi S, Yamaguchi R, Mizuno S, Komura M, Miyano S, Nakagawa H and Imoto S: ALPHLARD: A Bayesian method for analyzing HLA genes from whole genome sequence data. BMC Genomics. 19:7902018. View Article : Google Scholar : PubMed/NCBI

Bai Y, Wang D and Fury W: PHLAT: Inference of high-resolution HLA types from RNA and whole exome sequencing. Methods Mol Biol. 1802:193–201. 2018. View Article : Google Scholar : PubMed/NCBI

Orenbuch R, Filip I, Comito D, Shaman J, Pe'er I and Rabadan R: arcasHLA: High-resolution HLA typing from RNAseq. Bioinformatics. 36:33–40. 2020. View Article : Google Scholar :

Bauer DC, Zadoorian A, Wilson LOW; Melbourne Genomics Health Alliance; Thorne NP: Evaluation of computational programs to predict HLA genotypes from genomic sequencing data. Brief Bioinform. 19:179–187. 2018.

Kiyotani K, Mai TH and Nakamura Y: Comparison of exome-based HLA class I genotyping tools: Identification of platform-specific genotyping errors. J Hum Genet. 62:397–405. 2017. View Article : Google Scholar

Schumacher TN and Schreiber RD: Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015. View Article : Google Scholar : PubMed/NCBI

Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ and Osmanov S: Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses. 16:1433–1443. 2000. View Article : Google Scholar : PubMed/NCBI

Kessler JH, Benckhuijsen WE, Mutis T, Melief CJM, van der Burg SH and Drijfhout JW: Competition-based cellular peptide binding assay for HLA class I. Curr Protoc Immunol. Chapter 18: Unit 18.12. 2004. View Article : Google Scholar

Wulf M, Hoehn P and Trinder P: Identification and validation of T-cell epitopes using the IFN-gamma ELISPOT assay. Methods Mol Biol. 524:439–446. 2009. View Article : Google Scholar : PubMed/NCBI

Yang B, Jeang J, Yang A, Wu TC and Hung CF: DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 10:3153–3164. 2014. View Article : Google Scholar

Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, Wheeler DK, Sette A and Peters B: The immune epitope database (IEDB): 2018 Update. Nucleic Acids Res. 47(D1): D339–D343. 2019. View Article : Google Scholar :

Rammensee H, Bachmann J, Emmerich NP, Bachor OA and Stevanović S: SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar

Bhasin M, Singh H and Raghava GPS: MHCBN: A comprehensive database of MHC binding and non-binding peptides. Bioinformatics. 19:665–666. 2003. View Article : Google Scholar : PubMed/NCBI

Blass E and Ott PA: Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 18:215–229. 2021. View Article : Google Scholar : PubMed/NCBI

Garcia-Garijo A, Fajardo CA and Gros A: Determinants for neoantigen identification. Front Immunol. 10:13922019. View Article : Google Scholar : PubMed/NCBI

Falk K, Rötzschke O, Stevanović S, Jung G and Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 351:290–296. 1991. View Article : Google Scholar : PubMed/NCBI

Rötzschke O, Falk K, Stevanović S, Jung G, Walden P and Rammensee HG: Exact prediction of a natural T cell epitope. Eur J Immunol. 21:2891–2894. 1991. View Article : Google Scholar : PubMed/NCBI

Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, Brunak S and Lund O: Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12:1007–1017. 2003. View Article : Google Scholar : PubMed/NCBI

Nielsen M and Andreatta M: NetMHCpan-3.0; Improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8:332016. View Article : Google Scholar : PubMed/NCBI

Peters B and Sette A: Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics. 6:1322005. View Article : Google Scholar : PubMed/NCBI

Kim Y, Sidney J, Pinilla C, Sette A and Peters B: Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics. 10:3942009. View Article : Google Scholar : PubMed/NCBI

Lundegaard C, Lund O and Nielsen M: Prediction of epitopes using neural network based methods. J Immunol Methods. 374:26–34. 2011. View Article : Google Scholar :

Schueler-Furman O, Altuvia Y, Sette A and Margalit H: Structure-based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles. Protein Sci. 9:1838–1846. 2000. View Article : Google Scholar : PubMed/NCBI

Kumar N and Mohanty D: MODPROPEP: A program for knowledge-based modeling of protein-peptide complexes. Nucleic Acids Res. 35(Web Server Issue): W549–W555. 2007. View Article : Google Scholar : PubMed/NCBI

Hattotuwagama CK, Doytchinova IA and Flower DR: Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: In silico bioinformatic step-by-step guide using quantitative structure-activity relationships. Methods Mol Biol. 409:227–245. 2007. View Article : Google Scholar

Luo H, Ye H, Ng HW, Shi L, Tong W, Mendrick DL and Hong H: Machine learning methods for predicting HLA-peptide binding activity. Bioinform Biol Insights. 9(Suppl 3): S21–S29. 2015.

Zhang H, Lund O and Nielsen M: The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: Application to MHC-peptide binding. Bioinformatics. 25:1293–1299. 2009. View Article : Google Scholar :

Wang M, Lei C, Wang J, Li Y and Li M: TripHLApan: Predicting HLA molecules binding peptides based on triple coding matrix and transfer learning. Brief Bioinform. 25:bbae1542024. View Article : Google Scholar

Boehm KM, Bhinder B, Raja VJ, Dephoure N and Elemento O: Predicting peptide presentation by major histocompatibility complex class I: An improved machine learning approach to the immunopeptidome. BMC Bioinformatics. 20:72019. View Article : Google Scholar

Mei S, Li F, Xiang D, Ayala R, Faridi P, Webb GI, Illing PT, Rossjohn J, Akutsu T, Croft NP, et al: Anthem: A user customised tool for fast and accurate prediction of binding between peptides and HLA class I molecules. Brief Bioinform. 22:bbaa4152021. View Article : Google Scholar

Reche PA, Glutting JP and Reinherz EL: Prediction of MHC class I binding peptides using profile motifs. Hum Immunol. 63:701–709. 2002. View Article : Google Scholar : PubMed/NCBI

Reche PA, Glutting JP, Zhang H and Reinherz EL: Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics. 56:405–419. 2004. View Article : Google Scholar

Reche PA and Reinherz EL: Prediction of peptide-MHC binding using profiles. Methods Mol Biol. 409:185–200. 2007. View Article : Google Scholar

Buus S, Lauemøller SL, Worning P, Kesmir C, Frimurer T, Corbet S, Fomsgaard A, Hilden J, Holm A and Brunak S: Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens. 62:378–384. 2003. View Article : Google Scholar : PubMed/NCBI

Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O and Nielsen M: NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36(Web Server Issue): W509–W512. 2008. View Article : Google Scholar

Andreatta M and Nielsen M: Gapped sequence alignment using artificial neural networks: Application to the MHC class I system. Bioinformatics. 32:511–517. 2016. View Article : Google Scholar

Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A and Peters B: Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:22008. View Article : Google Scholar :

Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B and Nielsen M: NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 199:3360–3368. 2017. View Article : Google Scholar

Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S and Nielsen M: NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 61:1–13. 2009. View Article : Google Scholar

Reynisson B, Alvarez B, Paul S, Peters B and Nielsen M: NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48(W1): W449–W454. 2020. View Article : Google Scholar

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G and Gfeller D: Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol. 13:e10057252017. View Article : Google Scholar : PubMed/NCBI

Gfeller D, Schmidt J, Croce G, Guillaume P, Bobisse S, Genolet R, Queiroz L, Cesbron J, Racle J and Harari A: Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8⁺ T-cell epitopes. Cell Syst. 14:72–83.e5. 2023. View Article : Google Scholar

Liu G, Li D, Li Z, Qiu S, Li W, Chao CC, Yang N, Li H, Cheng Z, Song X, et al: PSSMHCpan: A novel PSSM-based software for predicting class I peptide-HLA binding affinity. Gigascience. 6:1–11. 2017. View Article : Google Scholar

O'Donnell TJ, Rubinsteyn A and Laserson U: MHCflurry 2.0: Improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 11:42–48.e7. 2020. View Article : Google Scholar

O'Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U and Hammerbacher J: MHCflurry: Open-source class I MHC binding affinity prediction. Cell Syst. 7:129–132.e4. 2018. View Article : Google Scholar

Phloyphisut P, Pornputtapong N, Sriswasdi S and Chuangsuwanich E: MHCSeqNet: A deep neural network model for universal MHC binding prediction. BMC Bioinformatics. 20:2702019. View Article : Google Scholar : PubMed/NCBI

Hu Y, Wang Z, Hu H, Wan F, Chen L, Xiong Y, Wang X, Zhao D, Huang W and Zeng J: ACME: Pan-specific peptide-MHC class I binding prediction through attention-based deep neural networks. Bioinformatics. 35:4946–4954. 2019. View Article : Google Scholar

Wu J, Wang W, Zhang J, Zhou B, Zhao W, Su Z, Gu X, Wu J, Zhou Z and Chen S: DeepHLApan: A deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity. Front Immunol. 10:25592019. View Article : Google Scholar : PubMed/NCBI

Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, et al: A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 38:199–209. 2020. View Article : Google Scholar

Shao XM, Bhattacharya R, Huang J, Sivakumar IKA, Tokheim C, Zheng L, Hirsch D, Kaminow B, Omdahl A, Bonsack M, et al: High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. Cancer Immunol Res. 8:396–408. 2020. View Article : Google Scholar

Yang X, Zhao L, Wei F and Li J: DeepNetBim: Deep learning model for predicting HLA-epitope interactions based on network analysis by harnessing binding and immunogenicity information. BMC Bioinformatics. 22:2312021. View Article : Google Scholar : PubMed/NCBI

Albert BA, Yang Y, Shao XM, Singh D, Smit KN, Anagnostou V and Karchin R: Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity. Nat Mach Intell. 5:861–872. 2023. View Article : Google Scholar : PubMed/NCBI

Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F and Hammer J: Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 17:555–561. 1999. View Article : Google Scholar

Singh H and Raghava GP: ProPred: Prediction of HLA-DR binding sites. Bioinformatics. 17:1236–1237. 2001. View Article : Google Scholar

Wan J, Liu W, Xu Q, Ren Y, Flower DR and Li T: SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics. 7:4632006. View Article : Google Scholar

Nielsen M, Lundegaard C and Lund O: Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 8:2382007. View Article : Google Scholar : PubMed/NCBI

Nielsen M and Lund O: NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 10:2962009. View Article : Google Scholar : PubMed/NCBI

Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B and Nielsen M: Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 154:394–406. 2018. View Article : Google Scholar

Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, Buus S and Lund O: Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol. 4:e10001072008. View Article : Google Scholar : PubMed/NCBI

Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S and Nielsen M: Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics. 67:641–650. 2015. View Article : Google Scholar :

Kaabinejadian S, Barra C, Alvarez B, Yari H, Hildebrand WH and Nielsen M: Accurate MHC motif deconvolution of immunopeptidomics data reveals a significant contribution of DRB3, 4 and 5 to the total DR immunopeptidome. Front Immunol. 13:8354542022. View Article : Google Scholar :

Pfeifer N and Kohlbacher O: Multiple instance learning allows MHC class II epitope predictions across alleles. Lect Notes Comput Sci. 5251:210–221. 2008. View Article : Google Scholar

Bordner AJ and Mittelmann HD: MultiRTA: A simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes. BMC Bioinformatics. 11:4822010. View Article : Google Scholar : PubMed/NCBI

Zhang L, Chen Y, Wong HS, Zhou S, Mamitsuka H and Zhu S: TEPITOPEpan: Extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules. PLoS One. 7:e304832012. View Article : Google Scholar

Chen B, Khodadoust MS, Olsson N, Wagar LE, Fast E, Liu CL, Muftuoglu Y, Sworder BJ, Diehn M, Levy R, et al: Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 37:1332–1343. 2019. View Article : Google Scholar : PubMed/NCBI

Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, Guillaume P, Coukos G, Harari A, Jandus C, et al: Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat Biotechnol. 37:1283–1286. 2019. View Article : Google Scholar

Racle J, Guillaume P, Schmidt J, Michaux J, Larabi A, Lau K, Perez MAS, Croce G, Genolet R, Coukos G, et al: Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity. 56:1359–1375.e13. 2023. View Article : Google Scholar : PubMed/NCBI

Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, Creech AL, Serrano LR, Nasir G, Nasrullah Y, et al: Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity. 51:766–779.e17. 2019. View Article : Google Scholar : PubMed/NCBI

Liu Z, Jin J, Cui Y, Xiong Z, Nasiri A, Zhao Y and Hu J: DeepSeqPanII: An interpretable recurrent neural network model with attention mechanism for peptide-HLA class II binding prediction. IEEE/ACM Trans Comput Biol Bioinform. 19:2188–2196. 2022. View Article : Google Scholar

Rammensee HG, Friede T and Stevanoviíc S: MHC ligands and peptide motifs: First listing. Immunogenetics. 41:178–228. 1995. View Article : Google Scholar

Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA and Strominger JL: Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 358:764–768. 1992. View Article : Google Scholar

Wang P, Sidney J, Dow C, Mothé B, Sette A and Peters B: A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4:e10000482008. View Article : Google Scholar : PubMed/NCBI

Yu K, Petrovsky N, Schönbach C, Koh JYL and Brusic V: Methods for prediction of peptide binding to MHC molecules: A comparative study. Mol Med. 8:137–148. 2002. View Article : Google Scholar

Peters B, Bui HH, Frankild S, Nielson M, Lundegaard C, Kostem E, Basch D, Lamberth K, Harndahl M, Fleri W, et al: A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol. 2:e652006. View Article : Google Scholar : PubMed/NCBI

Gowthaman U, Chodisetti SB, Parihar P and Agrewala JN: Evaluation of different generic in silico methods for predicting HLA class I binding peptide vaccine candidates using a reverse approach. Amino Acids. 39:1333–1342. 2010. View Article : Google Scholar : PubMed/NCBI

Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, Schitter EC, Blatnik R and Riemer AB: Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding data set. Cancer Immunol Res. 7:719–736. 2019. View Article : Google Scholar

Trolle T, Metushi IG, Greenbaum JA, Kim Y, Sidney J, Lund O, Sette A, Peters B and Nielsen M: Automated benchmarking of peptide-MHC class I binding predictions. Bioinformatics. 31:2174–2181. 2015. View Article : Google Scholar :

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA and Schreiber H: Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 23:516–526. 2013. View Article : Google Scholar :

Nogueira C, Kaufmann JK, Lam H and Flechtner JB: Improving cancer immunotherapies through empirical neoantigen selection. Trends Cancer. 4:97–100. 2018. View Article : Google Scholar

Liao WWP and Arthur JW: Predicting peptide binding to major histocompatibility complex molecules. Autoimmun Rev. 10:469–473. 2011. View Article : Google Scholar

Backert L and Kohlbacher O: Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med. 7:1192015. View Article : Google Scholar : PubMed/NCBI

Türeci Ö, Löwer M, Schrörs B, Lang M, Tadmor A and Sahin U: Challenges towards the realization of individualized cancer vaccines. Nat Biomed Eng. 2:566–569. 2018. View Article : Google Scholar

Schumacher TN, Scheper W and Kvistborg P: Cancer neoantigens. Annu Rev Immunol. 37:173–200. 2019. View Article : Google Scholar

Xie N, Shen G, Gao W, Huang Z, Huang C and Fu L: Neoantigens: Promising targets for cancer therapy. Signal Transduct Target Ther. 8:92023. View Article : Google Scholar :

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al: Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 7:134042016. View Article : Google Scholar : PubMed/NCBI

Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, et al: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 153:5586–5592. 1994. View Article : Google Scholar : PubMed/NCBI

Bjerregaard AM, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z and Eklund AC: An analysis of natural T cell responses to predicted tumor neoepitopes. Front Immunol. 8:15662017. View Article : Google Scholar : PubMed/NCBI

Shah K, Al-Haidari A, Sun J and Kazi JU: T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 6:4122021. View Article : Google Scholar

Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, Lund O and Nielsen M: An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol. 35:2295–2303. 2005. View Article : Google Scholar : PubMed/NCBI

Stranzl T, Larsen MV, Lundegaard C and Nielsen M: NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics. 62:357–368. 2010. View Article : Google Scholar : PubMed/NCBI

Zhou C, Zhu C and Liu Q: Toward in silico identification of tumor neoantigens in immunotherapy. Trends Mol Med. 25:980–992. 2019. View Article : Google Scholar : PubMed/NCBI

Chen P, Chen D, Bu D, Gao J, Qin W, Deng K, Ren L, She S, Xu W, Yang Y, et al: Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. J Immunother Cancer. 11:e0063342023. View Article : Google Scholar : PubMed/NCBI

Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, et al: Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother. 63:1199–1211. 2014. View Article : Google Scholar :

Slota M, Lim JB, Dang Y and Disis ML: ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 10:299–306. 2011. View Article : Google Scholar : PubMed/NCBI

Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O and Tarkowski A: A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 65:109–121. 1983. View Article : Google Scholar

Taguchi T, McGhee JR, Coffman RL, Beagley KW, Eldridge JH, Takatsu K and Kiyono H: Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J Immunol Methods. 128:65–73. 1990. View Article : Google Scholar

Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM and Zavala F: Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods. 181:45–54. 1995. View Article : Google Scholar : PubMed/NCBI

Verneris MR, Karimi M, Baker J, Jayaswal A and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004. View Article : Google Scholar : PubMed/NCBI

Wonderlich J, Shearer G, Livingstone A, Brooks A, Soloski MJ and Presby MM: Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 120:3.11.1–3.11.29. 2018.

Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, et al: Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study. Clin Cancer Res. 12:1859–1867. 2006. View Article : Google Scholar : PubMed/NCBI

Clevers H and Tuveson DA: Organoid models for cancer research. Annu Rev Cancer Biol. 3:223–234. 2019. View Article : Google Scholar

Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, et al: A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 180:188–204.e22. 2020. View Article : Google Scholar

Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, et al: Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 173:515–528.e17. 2018. View Article : Google Scholar

Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, van den Brink S, Schumacher TN and Voest EE: Tumor organoid-T-cell coculture systems. Nat Protoc. 15:15–39. 2020. View Article : Google Scholar

Weng G, Tao J, Liu Y, Qiu J, Su D, Wang R, Luo W and Zhang T: Organoid: Bridging the gap between basic research and clinical practice. Cancer Lett. 572:2163532023. View Article : Google Scholar : PubMed/NCBI

Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol. 7:118–130. 2007. View Article : Google Scholar : PubMed/NCBI

Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA and Manz MG: Human hemato-lymphoid system mice: Current use and future potential for medicine. Annu Rev Immunol. 31:635–674. 2013. View Article : Google Scholar : PubMed/NCBI

Morillon YM II, Sabzevari A, Schlom J and Greiner JW: The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. 40:5329–5341. 2020. View Article : Google Scholar

Ehx G, Ritacco C and Baron F: Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice. Biomark Res. 12:1392024. View Article : Google Scholar : PubMed/NCBI

Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, Shultz LD and Brehm MA: Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 20:192–206. 2023. View Article : Google Scholar : PubMed/NCBI

Guil-Luna S, Sedlik C and Piaggio E: Humanized mouse models to evaluate cancer immunotherapeutics. Annu Rev Cancer Biol. 5:119–136. 2021. View Article : Google Scholar

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS and Piaggio E: Humanized mice for the study of immuno-oncology. Trends Immunol. 39:748–763. 2018. View Article : Google Scholar : PubMed/NCBI

Camacho RE, Wnek R, Fischer P, Shah K, Zaller DM, Woods A, La Monica N, Aurisicchio L, Fitzgerald-Bocarsly P and Koo GC: Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: A model of SCID-hu mouse for vaccine development. Exp Hematol. 35:1219–1230. 2007. View Article : Google Scholar

Spranger S, Frankenberger B and Schendel DJ: NOD/scid IL-2Rg(null) mice: A preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med. 10:302012. View Article : Google Scholar

Li R, Han DS, Shi JP, Han YX, Tan P, Zhang R and Li JM: Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. Biochim Biophys Acta Rev Cancer. 1874:1884202020. View Article : Google Scholar

Ahmed J, Das B, Shin S and Chen A: Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers (Basel). 15:58412023. View Article : Google Scholar : PubMed/NCBI

Teixido C, Castillo P, Martinez-Vila C, Arance A and Alos L: Molecular markers and targets in melanoma. Cells. 10:23202021. View Article : Google Scholar : PubMed/NCBI

Yarchoan M, Hopkins A and Jaffee EM: Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI

Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al: A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 183:347–362.e24. 2020. View Article : Google Scholar : PubMed/NCBI

Mørk SK, Kadivar M, Bol KF, Draghi A, Wulff Westergaard MC, Skadborg SK, Overgaard N, Sørensen AB, Rasmussen IS, Andreasen LV, et al: Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF^®09b, in patients with metastatic melanoma. Oncoimmunology. 11:20232552022. View Article : Google Scholar

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, et al: Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet. 403:632–644. 2024. View Article : Google Scholar : PubMed/NCBI

Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, et al: Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 6:262021. View Article : Google Scholar :

Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, et al: T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14:2209–2223. 2024. View Article : Google Scholar : PubMed/NCBI

Lee JM, Spicer J, Nair S, Khattak A, Brown M, Meehan RS, Shariati NM, Deng X, Samkari A and Chaft JE: The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC). J Clin Oncol. 42(16 Suppl): TPS81162024. View Article : Google Scholar

Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, et al: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 9:e0025312021. View Article : Google Scholar : PubMed/NCBI

Gao S, Wang J, Zhu Z, Fang J, Zhao Y, Liu Z, Qin H, Wei Y, Xu H, Dan X, et al: Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient. Immunotherapy. 15:57–69. 2023. View Article : Google Scholar : PubMed/NCBI

Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, Poran A, Sheen JH, Kohler V, Esaulova E, et al: Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 40:1010–1026.e11. 2022. View Article : Google Scholar

McCann K, von Witzleben A, Thomas J, Wang C, Wood O, Singh D, Boukas K, Bendjama K, Silvestre N, Nielsen FC, et al: Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. J Immunother Cancer. 10:e0038212022. View Article : Google Scholar :

Moen MD: Bevacizumab: In previously treated glioblastoma. Drugs. 70:181–189. 2010. View Article : Google Scholar

Engelhardt B: The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des. 14:1555–1565. 2008. View Article : Google Scholar : PubMed/NCBI

Johanns TM, Bowman-Kirigin JA, Liu C and Dunn GP: Targeting neoantigens in glioblastoma: An overview of cancer immunogenomics and translational implications. Neurosurgery. 64(CN Suppl 1): S165–S176. 2017. View Article : Google Scholar

Dang L, Yen K and Attar EC: IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 27:599–608. 2016. View Article : Google Scholar

Ni YQ, Shen PB, Wang XC, Liu HY, Luo HY and Han XZ: The roles of IDH1 in tumor metabolism and immunity. Future Oncol. 18:3941–3953. 2022. View Article : Google Scholar

de la Fuente MI: Targeting IDH1/IDH2 mutations in gliomas. Curr Opin Neurol. 35:787–793. 2022. View Article : Google Scholar : PubMed/NCBI

Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B and Finocchiaro G: Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 3:42015. View Article : Google Scholar : PubMed/NCBI

Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, et al: A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 592:463–468. 2021. View Article : Google Scholar :

Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, Green E, Sanghvi K, Karapanagiotou-Schenkel I, Harting I, et al: Atim-33. Noa-16: A first-in-man multicenter phase I clinical trial of the German neurooncology working group evaluating a mutation-specific peptide vaccine targeting idh1r132h in patients with newly diagnosed malignant astrocytomas. Neuro Oncol. 20(Suppl 6): vi8–vi9. 2018. View Article : Google Scholar

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 565:240–245. 2019. View Article : Google Scholar

Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y, Ichikawa T, et al: A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 21:348–359. 2019. View Article : Google Scholar :

Bruix J and Sherman M; Practice Guidelines Committee American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar

Tampaki M, Papatheodoridis GV and Cholongitas E: Intrahepatic recurrence of hepatocellular carcinoma after resection: An update. Clin J Gastroenterol. 14:699–713. 2021. View Article : Google Scholar : PubMed/NCBI

European Association for the Study of the Liver: EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar

Charneau J, Suzuki T, Shimomura M, Fujinami N and Nakatsura T: Peptide-based vaccines for hepatocellular carcinoma: A review of recent advances. J Hepatocell Carcinoma. 8:1035–1054. 2021. View Article : Google Scholar

Liu C, Shao J, Dong Y, Xu Q, Zou Z, Chen F, Yan J, Liu J, Li S, Liu B and Shen J: Advanced HCC patient benefit from neoantigen reactive T cells based immunotherapy: A case report. Front Immunol. 12:6851262021. View Article : Google Scholar :

Cai Z, Su X, Qiu L, Li Z, Li X, Dong X, Wei F, Zhou Y, Luo L, Chen G, et al: Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 20:1642021. View Article : Google Scholar : PubMed/NCBI

Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, Wang W, Chen Z, Xiao H, Zhou Q, et al: Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol Res. 10:728–744. 2022. View Article : Google Scholar : PubMed/NCBI

Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, et al: Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 23:5395–5404. 2017. View Article : Google Scholar

Guo Z, Yuan Y, Chen C, Lin J, Ma Q, Liu G, Gao Y, Huang Y, Chen L, Chen LZ, et al: Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ Precis Oncol. 6:342022. View Article : Google Scholar :

Yu YJ, Shan N, Li LY, Zhu YS, Lin LM, Mao CC, Hu TT, Xue XY, Su XP, Shen X and Cai ZZ: Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunol Immunother. 72:2045–2056. 2023. View Article : Google Scholar

Sultan H, Salazar AM and Celis E: Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol. 49:1014142020. View Article : Google Scholar : PubMed/NCBI

Zeng Y, Zhang W, Li Z, Zheng Y, Wang Y, Chen G, Qiu L, Ke K, Su X, Cai Z, et al: Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: Case report. J Immunother Cancer. 8:e0002172020. View Article : Google Scholar :

Chen Z, Zhang S, Han N, Jiang J, Xu Y, Ma D, Lu L, Guo X, Qiu M, Huang Q, et al: A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Front Immunol. 12:6916052021. View Article : Google Scholar

Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, et al: Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature. 639:463–473. 2025. View Article : Google Scholar : PubMed/NCBI

Rosenberg-Mogilevsky A, Siegfried Z and Karni R: Generation of tumor neoantigens by RNA splicing perturbation. Trends Cancer. 11:12–24. 2025. View Article : Google Scholar

Huang P, Wen F, Tuerhong N, Yang Y and Li Q: Neoantigens in cancer immunotherapy: Focusing on alternative splicing. Front Immunol. 15:14377742024. View Article : Google Scholar :

Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, et al: Systematic analysis of splice-site-creating mutations in cancer. Cell Rep. 23:270–281.e3. 2018. View Article : Google Scholar

Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, Fugmann T, Wong KK and Van Allen EM: Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 36:1056–1058. 2018. View Article : Google Scholar : PubMed/NCBI

Wang F, Cai G, Wang Y, Zhuang Q, Cai Z, Li Y, Gao S, Li F, Zhang C, Zhao B and Liu X: Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy. MedComm (2020). 5:e6672024. View Article : Google Scholar : PubMed/NCBI

Hu ZX, Guo XY, Li ZT, Meng ZQ and Huang SL: The neoantigens derived from transposable elements-A hidden treasure for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 1879:1891262024. View Article : Google Scholar

Li M, Wang Y, Wu P, Zhang S, Gong Z, Liao Q, Guo C, Wang F, Li Y, Zeng Z, et al: Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy. Cancer Lett. 563:2161902023. View Article : Google Scholar : PubMed/NCBI

Lang F, Schrörs B, Löwer M, Türeci Ö and Sahin U: Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 21:261–282. 2022. View Article : Google Scholar

Gurung HR, Heidersbach AJ, Darwish M, Chan PPF, Li J, Beresini M, Zill OA, Wallace A, Tong AJ, Hascall D, et al: Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol. 42:1107–1117. 2024. View Article : Google Scholar

Shen KY, Zhu Y, Xie SZ and Qin LX: Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives. J Hematol Oncol. 17:252024. View Article : Google Scholar : PubMed/NCBI

Cherepnev G, Volk HD and Kern F: Use of peptides and peptide libraries as T-cell stimulants in flow cytometric studies. Methods Cell Biol. 75:453–479. 2004. View Article : Google Scholar : PubMed/NCBI

Gascoigne NR: Do T cells need endogenous peptides for activation? Nat Rev Immunol. 8:895–900. 2008. View Article : Google Scholar

Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S and Wu B: Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Mol Ther. 29:555–570. 2021. View Article : Google Scholar

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar

Prehn RT and Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 18:769–778. 1957.PubMed/NCBI

Hao Q, Long YH, Yang Y, Deng YQ, Ding ZY, Yang L, Shu Y and Xu H: Development and clinical applications of therapeutic cancer vaccines with individualized and shared neoantigens. Vaccines (Basel). 12:7172024. View Article : Google Scholar

D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, et al: Adenoviral-based vaccine promotes neoantigen-specific CD8⁺ T cell stemness and tumor rejection. Sci Transl Med. 14:eabo76042022. View Article : Google Scholar

Tsimberidou AM: Targeted therapy in cancer. Cancer Chemother Pharmacol. 76:1113–1132. 2015. View Article : Google Scholar